A proprietary tool that evaluates the quality of research practice.
Uses machine learning models to predict the probability of clinical success based on non-clinical data quality.
Helps identify the most robust non-clinical data and allows low quality projects to “fail faster.”
PAASPort® is optimized for nonclinical research and many kinds of organizations can benefit from this service, including:
PAASPort® enables the early detection of potential bias, avoiding wasted resources investing in low-quality research data.
PAASPort® provides a third-party quality assessment, increasing assurance that funding is applied to research with greater translational potential.
PAASPort® enhances the value of conventional due diligence by delivering expert statements about the probability that a given set of preclinical data is robust enough to support a successful drug discovery project.
Contract Research Organizations
PAASPort® certification identifies research procedures as unbiased and data of high quality, offering a competitive advantage.
Having a research process evaluated with PAASPort® will show funders and investors that research is aligned with best practices.
PAASPort® certification increases confidence that research projects are on the right track to attract investment and generate the next blockbuster treatment.